Akero Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Akero Therapeutics generated cash of -$145,367,000, which is less than the previous year. Cash used in financing activities reached the amount of $353,316,000 last year. Net change in cash is therefore -$15,674,000.
Cash Flow
| 2017 | -4.38M | 0 | 5M |
|---|---|---|---|
| 2018 | -4.62M | -5M | 85.00M |
| 2019 | -35.62M | -71.51M | 95.98M |
| 2020 | -70.80M | -9.76M | 203.10M |
| 2021 | -79.68M | 42.28M | 602K |
| 2022 | -92.51M | -63.82M | 255.63M |
| 2023 | -145.36M | -223.62M | 353.31M |
AKRO Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 249.88M | 150.59M | 187.39M | 64.84M | 76M | 618K | -20K |
Operating activities | |||||||
Net income | -151.75M | -112.03M | -100.77M | -79.20M | -43.75M | -81.71M | -4.56M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 29K | 43K | 41K | 17K | -104K | 0 | 0 |
Stock-based compensation expense | 21.49M | 23.24M | 10.05M | 6.02M | 1.77M | 121K | 0 |
| Deferred income tax benefit | 21.49M | 23.24M | 10.05M | 6.02M | 1.77M | 121K | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -645K | 968K | 3.27M | 2.48M | -426K | 1.31M | 60K |
Cash generated by operating activities | -145.36M | -92.51M | -79.68M | -70.80M | -35.62M | -4.62M | -4.38M |
Investing activities | |||||||
Purchases Of Investments | -433.12M | -101.44M | -43.56M | -115.03M | -71.51M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -148K | 0 | -5M | 0 |
Acquisitions Net | 0 | 0 | 0 | 9.61K | 0 | 0 | 0 |
Cash generated by investing activities | -223.62M | -63.82M | 42.28M | -9.76M | -71.51M | -5M | 0 |
Financing activities | |||||||
Common Stock Issued | 335.42M | 241.2M | 602K | 203.05M | 95.45M | 85.00M | 5M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 15M | 10M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 353.31M | 255.63M | 602K | 203.10M | 95.98M | 85.00M | 5M |
Net Change In Cash | -15.67M | 99.29M | -36.79M | 122.54M | -11.15M | 75.38M | 618K |
Cash at end of period | 234.20M | 249.88M | 150.59M | 187.39M | 64.84M | 76M | 598K |
| Data source | Data source | Data source | Data source | Data source |